Psagot Investment House Ltd. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.9% during the 1st quarter, Holdings Channel reports. The firm owned 585 shares of the biopharmaceutical company’s stock after selling 250 shares during the period. Psagot Investment House Ltd.’s holdings in Gilead Sciences were worth $38,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the company. Cubist Systematic Strategies LLC increased its holdings in Gilead Sciences by 5.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 128,406 shares of the biopharmaceutical company’s stock valued at $8,299,000 after acquiring an additional 6,552 shares during the last quarter. Optimal Asset Management Inc. bought a new stake in Gilead Sciences in the 1st quarter valued at $1,645,000. Man Group plc increased its holdings in Gilead Sciences by 2.5% in the 1st quarter. Man Group plc now owns 1,252,398 shares of the biopharmaceutical company’s stock valued at $80,943,000 after acquiring an additional 30,087 shares during the last quarter. California State Teachers Retirement System increased its holdings in Gilead Sciences by 1.0% in the 1st quarter. California State Teachers Retirement System now owns 2,339,377 shares of the biopharmaceutical company’s stock valued at $151,194,000 after acquiring an additional 23,892 shares during the last quarter. Finally, Ameritas Investment Company LLC bought a new stake in Gilead Sciences in the 1st quarter valued at $220,000. Hedge funds and other institutional investors own 76.78% of the company’s stock.
NASDAQ:GILD opened at $68.41 on Thursday. Gilead Sciences, Inc. has a one year low of $56.56 and a one year high of $77.25. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.18 and a current ratio of 1.37. The company has a market cap of $85.80 billion, a price-to-earnings ratio of 9.23, a P/E/G ratio of 0.64 and a beta of 0.38. The firm has a 50-day simple moving average of $67.84.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 29th. Investors of record on Tuesday, June 15th were paid a dividend of $0.71 per share. The ex-dividend date was Monday, June 14th. This represents a $2.84 annualized dividend and a dividend yield of 4.15%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.06%.
A number of equities analysts have commented on the stock. Oppenheimer assumed coverage on shares of Gilead Sciences in a research note on Monday, June 28th. They issued a “buy” rating and a $100.00 price objective for the company. Redburn Partners raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a research note on Tuesday, March 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Friday, May 7th. Finally, SVB Leerink lifted their price target on shares of Gilead Sciences from $72.00 to $74.00 and gave the stock an “outperform” rating in a research note on Friday, April 30th. Ten equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $99.22.
In related news, Director Richard James Whitley sold 20,282 shares of the business’s stock in a transaction that occurred on Monday, May 3rd. The shares were sold at an average price of $64.57, for a total transaction of $1,309,608.74. Following the completion of the transaction, the director now owns 51,404 shares in the company, valued at approximately $3,319,156.28. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.12% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Featured Article: How to Invest in the Dividend Aristocrat Index
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.